Logo image of CRDL

CARDIOL THERAPEUTICS INC-A (CRDL) Stock Fundamental Analysis

NASDAQ:CRDL - Nasdaq - CA14161Y2006 - Common Stock - Currency: USD

1.12  +0.02 (+1.82%)

After market: 1.12 0 (0%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CRDL. CRDL was compared to 198 industry peers in the Pharmaceuticals industry. CRDL has a bad profitability rating. Also its financial health evaluation is rather negative. CRDL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CRDL has reported negative net income.
In the past year CRDL has reported a negative cash flow from operations.
In the past 5 years CRDL always reported negative net income.
In the past 5 years CRDL always reported negative operating cash flow.
CRDL Yearly Net Income VS EBIT VS OCF VS FCFCRDL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of CRDL (-206.26%) is worse than 87.88% of its industry peers.
With a Return On Equity value of -346.42%, CRDL is not doing good in the industry: 74.75% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -206.26%
ROE -346.42%
ROIC N/A
ROA(3y)-54.17%
ROA(5y)-76.13%
ROE(3y)-66.78%
ROE(5y)-89.83%
ROIC(3y)N/A
ROIC(5y)N/A
CRDL Yearly ROA, ROE, ROICCRDL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRDL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRDL Yearly Profit, Operating, Gross MarginsCRDL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -10K -20K -30K -40K

More info and screens

3

2. Health

2.1 Basic Checks

CRDL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRDL Yearly Shares OutstandingCRDL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
CRDL Yearly Total Debt VS Total AssetsCRDL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -9.40, we must say that CRDL is in the distress zone and has some risk of bankruptcy.
CRDL has a Altman-Z score of -9.40. This is in the lower half of the industry: CRDL underperforms 71.21% of its industry peers.
CRDL has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
CRDL has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -9.4
ROIC/WACCN/A
WACCN/A
CRDL Yearly LT Debt VS Equity VS FCFCRDL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

CRDL has a Current Ratio of 2.49. This indicates that CRDL is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.49, CRDL perfoms like the industry average, outperforming 47.98% of the companies in the same industry.
A Quick Ratio of 2.49 indicates that CRDL has no problem at all paying its short term obligations.
With a Quick ratio value of 2.49, CRDL perfoms like the industry average, outperforming 53.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.49
Quick Ratio 2.49
CRDL Yearly Current Assets VS Current LiabilitesCRDL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

CRDL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.91%.
EPS 1Y (TTM)-15.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 37.86% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3%
EPS Next 2Y-22.47%
EPS Next 3Y17.78%
EPS Next 5Y37.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRDL Yearly Revenue VS EstimatesCRDL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
CRDL Yearly EPS VS EstimatesCRDL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRDL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRDL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRDL Price Earnings VS Forward Price EarningsCRDL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRDL Per share dataCRDL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3

4.3 Compensation for Growth

A more expensive valuation may be justified as CRDL's earnings are expected to grow with 17.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.47%
EPS Next 3Y17.78%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRDL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARDIOL THERAPEUTICS INC-A

NASDAQ:CRDL (5/1/2025, 8:53:39 PM)

After market: 1.12 0 (0%)

1.12

+0.02 (+1.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-31 2025-03-31/amc
Earnings (Next)05-20 2025-05-20
Inst Owners9.66%
Inst Owner Change0.03%
Ins Owners4.65%
Ins Owner ChangeN/A
Market Cap92.52M
Analysts82.86
Price Target7.27 (549.11%)
Short Float %2.59%
Short Ratio8.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.24%
Min EPS beat(2)-47.06%
Max EPS beat(2)24.59%
EPS beat(4)2
Avg EPS beat(4)-6.52%
Min EPS beat(4)-47.06%
Max EPS beat(4)24.59%
EPS beat(8)6
Avg EPS beat(8)7.31%
EPS beat(12)10
Avg EPS beat(12)12.33%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.51%
PT rev (3m)6.79%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.27
P/tB 12.27
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -206.26%
ROE -346.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.17%
ROA(5y)-76.13%
ROE(3y)-66.78%
ROE(5y)-89.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.48%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.49
Quick Ratio 2.49
Altman-Z -9.4
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)20.75%
Cap/Depr(5y)71.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y-3%
EPS Next 2Y-22.47%
EPS Next 3Y17.78%
EPS Next 5Y37.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.74%
EBIT Next 3Y-0.33%
EBIT Next 5Y45.6%
FCF growth 1Y-16.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.22%
OCF growth 3YN/A
OCF growth 5YN/A